Lateral Decubitus position: Lateral Decubitus position with a special device
Lateral Decubitus device: Lateral Decubitus postion with a special device
Study summary
A Prospective Study on the Application of Lateral Decubitus Position in Patients with Left Breast Cancer Undergoing Adjuvant Radiotherapy
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Voluntary signing of the informed consent form
* Female patients aged 18-70 years
* Newly diagnosed left-sided breast cancer confirmed by histopathology
* No evidence of distant metastasis
* Undergoing modified radical mastectomy or breast-conserving surgery
* ECOG performance status of 0, 1, or 2
* Tolerance to radiotherapy
* Radiation field covering the entire left breast/chest wall ± regional lymphatic drainage area
Exclusion Criteria:
* Bilateral breast cancer at diagnosis
* History of breast reconstruction or implant placement on the affected side
* Prior radiotherapy to the chest or supraclavicular region
* Patients deemed unsuitable for the study based on the investigator's judgment
Primary outcome measure(s)
Radiotherapy Planning Dose-Volume Parameter -Volume of 5Gy heart dose — From study participation to the completion of the radiotherapy plan up to 2 years Volume of 5Gy heart dose
Radiotherapy Planning Dose-Volume Parameter -Max dose of LAD — From study participation to the completion of the radiotherapy plan up to 2 years Max dose of LAD
Radiotherapy Planning Dose-Volume Parameter -mean heart dose — From study participation to the completion of the radiotherapy plan up to 2 years mean heart dose
Major Cardiovascular Events — From the initiation of radiotherapy to 2 years after its completion. Major cardiovascular events include death due to coronary artery disease or other cardiac diseases, myocardial infarction, coronary revascularization, or hospitalization due to a major cardiovascular event (such as heart failure, valvular disease, arrhythmia, unstable angina, or other significant cardiovascular conditions).
Subclinical Cardiovascular Events- Left ventricular ejection fraction (LVEF) — From the initiation of radiotherapy to 2 years after its completion. Subclinical cardiovascular events include electrocardiographic abnormalities and echocardiographic abnormalities, such as:
\- Left ventricular ejection fraction (LVEF) \< 50% or a reduction of \> 10%.
Subclinical Cardiovascular Events- Left ventricular diastolic dysfunction — From the initiation of radiotherapy to 2 years after its completion. Subclinical cardiovascular events include electrocardiographic abnormalities and echocardiographic abnormalities, such as:
\- Left ventricular diastolic dysfunction, meeting at least two of the following four criteria:
1. Mean E/e' \> 14 (E/e'-lateral wall \> 13 or E/Em-septum \> 15).
2. e'-lateral wall \< 10 or e'-septum \< 7.
3. Tricuspid regurgitation velocity \> 2.8 m/s.
4. Left atrial volume index \> 34 mL/m².
Trial sites (2)
Facility
City
Region
Status
Nanfang Hospital, Southern Medical University
Guangzhou
Guangdong Provinse
Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou
Guangdong Provinse
Recruiting
More Nanfang Hospital, Southern Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.